Affymax, Inc. (AFFY)
USD 0.0
(242.86%)
USD 0.0
(242.86%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2013 | 39.38 Million USD | -72.16% |
| 2012 | 141.45 Million USD | 29.62% |
| 2011 | 109.12 Million USD | -14.05% |
| 2010 | 126.96 Million USD | -34.5% |
| 2009 | 193.84 Million USD | 12.97% |
| 2008 | 171.58 Million USD | 83.56% |
| 2007 | 93.47 Million USD | 42.85% |
| 2006 | 65.43 Million USD | 91.99% |
| 2005 | 34.08 Million USD | 53.05% |
| 2004 | 22.26 Million USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 28.44 Million USD | 364.76% |
| 2001 | -10.74 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2014 Q1 | 1.49 Million USD | 77.53% |
| 2014 Q2 | 1.06 Million USD | -28.6% |
| 2013 Q2 | 2.76 Million USD | -79.81% |
| 2013 Q3 | 1.38 Million USD | -49.76% |
| 2013 Q4 | 841 Thousand USD | -39.41% |
| 2013 Q1 | 13.68 Million USD | -64.02% |
| 2013 FY | 39.38 Million USD | -72.16% |
| 2012 FY | 141.45 Million USD | 29.62% |
| 2012 Q4 | 38.03 Million USD | 1.15% |
| 2012 Q3 | 37.59 Million USD | 10.14% |
| 2012 Q2 | 34.13 Million USD | 7.72% |
| 2012 Q1 | 31.68 Million USD | -4.25% |
| 2011 Q4 | 33.09 Million USD | 43.67% |
| 2011 FY | 109.12 Million USD | -14.05% |
| 2011 Q2 | 26.68 Million USD | 1.39% |
| 2011 Q3 | 23.03 Million USD | -13.67% |
| 2011 Q1 | 26.31 Million USD | 42.42% |
| 2010 Q2 | 37.08 Million USD | -12.78% |
| 2010 FY | 126.96 Million USD | -34.5% |
| 2010 Q4 | 18.47 Million USD | -36.06% |
| 2010 Q3 | 28.89 Million USD | -22.07% |
| 2010 Q1 | 42.51 Million USD | -12.56% |
| 2009 Q2 | 49.46 Million USD | 3.35% |
| 2009 FY | 193.84 Million USD | 12.97% |
| 2009 Q4 | 48.61 Million USD | 1.51% |
| 2009 Q3 | 47.89 Million USD | -3.18% |
| 2009 Q1 | 47.86 Million USD | -7.69% |
| 2008 Q3 | 48.08 Million USD | 24.13% |
| 2008 Q2 | 38.74 Million USD | 17.74% |
| 2008 Q4 | 51.85 Million USD | 7.82% |
| 2008 FY | 171.58 Million USD | 83.56% |
| 2008 Q1 | 32.9 Million USD | 6.2% |
| 2007 Q4 | 30.98 Million USD | 27.1% |
| 2007 Q2 | 20.92 Million USD | 21.73% |
| 2007 Q1 | 17.19 Million USD | 33.62% |
| 2007 FY | 93.47 Million USD | 42.85% |
| 2007 Q3 | 24.37 Million USD | 16.49% |
| 2006 Q4 | 12.86 Million USD | 18.57% |
| 2006 Q3 | 10.85 Million USD | -64.87% |
| 2006 FY | 65.43 Million USD | 91.99% |
| 2006 Q2 | 30.88 Million USD | 184.99% |
| 2006 Q1 | 10.83 Million USD | 131.8% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 100.0% |
| 2005 Q4 | -34.08 Million USD | 0.0% |
| 2005 FY | 34.08 Million USD | 53.05% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | 22.26 Million USD | 0.0% |
| 2004 Q4 | -22.26 Million USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2003 FY | - USD | -100.0% |
| 2002 FY | 28.44 Million USD | 364.76% |
| 2001 FY | -10.74 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -2849.31% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -681.151% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -33.272% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1666.284% |
| Rebus Holdings, Inc. | 664 Thousand USD | -5831.627% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -5.718% |
| Qrons Inc. | 643.67 Thousand USD | -6018.907% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -10010.225% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 31.431% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -9379.661% |
| Skye Bioscience, Inc. | 13.54 Million USD | -190.724% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 54.617% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -700.868% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -14948.562% |
| SQZ Biotechnologies Company | 85.61 Million USD | 53.999% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -1250.577% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -2522.413% |
| Mesoblast Limited | 5.9 Million USD | -567.333% |
| Marizyme, Inc. | 19.23 Million USD | -104.711% |
| Genus plc | 147.7 Million USD | 73.334% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -348.627% |
| Pharming Group N.V. | 225.49 Million USD | 82.533% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1822.483% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2835.869% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -372.311% |
| ContraFect Corporation | 56.88 Million USD | 30.767% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -793.376% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -2563.462% |
| IMV Inc. | 37.7 Million USD | -4.447% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -1311.504% |
| MultiCell Technologies, Inc. | 567.42 USD | -6941142.818% |
| ONE Bio Corp. | 6.44 Million USD | -511.214% |
| Accustem Sciences Inc. | 3.74 Million USD | -951.297% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 54.173% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -7303.912% |
| Q BioMed Inc. | 3.43 Million USD | -1046.065% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -59.361% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1398.979% |
| Biomind Labs Inc. | 994.18 Thousand USD | -3861.649% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 60.348% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -2138.25% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -486.274% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -2012.563% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 157644.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -146.005% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -2046.265% |
| GB Sciences, Inc. | 1.42 Million USD | -2672.668% |
| Alpha Cognition Inc. | 9.7 Million USD | -305.807% |
| HST Global, Inc. | 140.9 Thousand USD | -27851.77% |
| CSL Limited | 3.44 Billion USD | 98.858% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -3401.258% |
| Halberd Corporation | 74.84 Thousand USD | -52525.531% |
| Enzolytics Inc. | 2.17 Million USD | -1707.106% |
| Agentix Corp. | 1.37 Million USD | -2771.21% |
| Resverlogix Corp. | 12.71 Million USD | -209.833% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -978.86% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 97.432% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -3672.605% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1537.716% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -2393.803% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -1056.718% |
| AVAX Technologies, Inc. | 7.31 Million USD | -438.777% |
| Zenith Capital Corp. | 8.94 Million USD | -340.411% |
| Genscript Biotech Corporation | 825.34 Million USD | 95.228% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -225983.462% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1504.111% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -22864.393% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1950.387% |
| Kadimastem Ltd | 2.41 Million USD | -1534.198% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1897.227% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -262.437% |
| BioStem Technologies, Inc. | 22.97 Million USD | -71.431% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -21602.069% |
| LadRx Corporation | 3.81 Million USD | -933.268% |
| Cell Source, Inc. | 4.32 Million USD | -810.586% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -4164.816% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -4164.816% |
| NovAccess Global Inc. | 2.46 Million USD | -1496.669% |
| Itoco Inc. | 919.14 Thousand USD | -4185.079% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -829.263% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -3419.75% |
| Mobile Lads Corp. | 554.54 Thousand USD | -7002.386% |
| CytoDyn Inc. | 18.05 Million USD | -118.108% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -156386.154% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -17796.382% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -2674.068% |
| SYBLEU INC | 160.87 Thousand USD | -24382.21% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -2068.45% |
| International Stem Cell Corporation | 5.27 Million USD | -647.221% |
| Bioxytran, Inc. | 3.82 Million USD | -931.007% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -74718.586% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -193509.595% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -8.603% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -2334.24% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -5252.559% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -1166.024% |
| Neutra Corp. | 243.82 Thousand USD | -16053.654% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -125.617% |
| PureTech Health plc | 144.59 Million USD | 72.762% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -92.222% |
| IXICO plc | 4.7 Million USD | -736.754% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -347.721% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 66.551% |
| CSL Limited | 3.89 Billion USD | 98.988% |
| Cellectis S.A. | 97.32 Million USD | 59.529% |